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THE EFFECT OF POSTOPERATIVE KERATOMETRY ON VISUAL ACUITY 
AFTER CORNEAL REFRACTIVE LASER SURGERY 
 
DALLAS J. PETERS 
ABSTRACT 
PURPOSE: To determine if there is a relationship between eyes with flat corneas (as 
defined by calculated postoperative keratometry values of <38D) undergoing either 
LASIK (Laser-assisted in Situ Keratomileusis), LASEK (Laser-assisted Subepithelial 
Keratectomy), or PRK (Photorefractive Keratectomy) corneal refractive surgery and loss 
of 1 or more lines of postoperative BCVA, and if there is an advantage to undergoing 
either LASIK or ASA in eyes meeting flat cornea criteria.   
METHODS: A retrospective analysis of 191 candidate eyes with calculated 
postoperative keratometry values <38D were identified and matched by manifest 
refraction and surgery type to 191 control eyes with calculated postoperative keratometry 
values ≥38D. Both candidate groups and control groups were further stratified into 
subgroups based on degree of calculated postoperative keratometry. Candidate 
subgroups: Subgroup 1a (K<35D), Subgroup 2a (K=35-35.99D), Subgroup 3a (K=36-
36.99D), and Subgroup 4a (K=37-37.99D). Control subgroups: Subgroup 1b (K=38-
38.99D), Subgroup 2b (K=39-39.99D), Subgroup 3b (K=40-40.99D) and Subgroup 4b 
(K≥41D). All patients had undergone corneal refractive eye surgery procedures LASIK, 
LASEK, or PRK at Boston Eye Group/Boston Laser in Brookline MA between 
December 2008 and November 2016. All LASIK flaps were created using the 
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femtosecond laser IntraLase iFS60 Laser (Abbott Medical Optics Inc.). All surface 
ablation procedures were performed using the excimer lasers VISX STAR S4 IR Excimer 
Laser System (Abbot Medical Optics Inc.) or WaveLight EX500 Excimer Laser (Alcon 
Laboratories Inc.). Visual acuity outcomes measuring preoperative and postoperative 
BCVA and loss of BCVA were recorded as part of the patient’s medical chart and were 
statistically analyzed to determine correlations.  
RESULTS: Our data showed no significant differences between overall candidate 
(K<38D) and control (K≥38D) group mean preoperative BCVA (p<0.23) or mean 
postoperative BCVA (p<0.13). A total of 15 out of 191 (7.9%) candidate eyes lost 1 or 
more lines of BCVA in comparison to 23 total control eyes (12.0%) that lost 1 or more 
lines of BCVA postoperatively. When evaluating subgroup data, Candidate Subgroup 1a 
(K<35D) showed a significant (p<0.02) decrease in BCVA when compared to other 
candidate subgroups. Additionally, Control Subgroup 1b (K=38=38.99D) and Control 
Subgroup 2b (39-39.99D) showed a significant (p<0.001 and p<0.02 respectively) 
decrease in BCVA compared to other control subgroups. A total of 231 total candidate 
and control eyes underwent LASIK and a total of 151 total candidate and control eyes 
underwent ASA. Overall, 17 out of the 231 (7.4%) eyes undergoing LASIK lost BCVA 
compared to the 21 out of 151 (13.9%) eyes undergoing ASA that lost BCVA which was 
significant (p<0.04).  
CONCLUSION: This study did not find evidence to support that the overall flat cornea 
group (K<38D) lost postoperative BCVA when compared to a control group of eyes with 
normal keratometry values. However, our data indicated that when the candidate group 
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was stratified by degree of corneal curvature, patients with very flat corneas (K<35D) 
may be at increased risk of losing BCVA though further studies are needed. Additionally, 
eyes undergoing ASA may be at increased risk of losing BCVA though further studies 
are needed.  
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INTRODUCTION 
It is estimated that over 1 billion people worldwide currently suffer from poor 
vision related to correctable refractive errors, also known as ametropia (Durr et al., 2014). 
With approximately 75% of Americans currently requiring some sort of corrective 
eyewear, and that number expected to grow due to an aging population and increasing 
prevalence of chronic diseases linked to unhealthy lifestyles (“NHIS - Tables of 
Summary Health Statistics,” 2015), correcting ocular refractive errors will continue to be 
essential in the United States. The four most common types of refractive error in the US 
are myopia, hyperopia, presbyopia, and astigmatism. 
 Types of Refractive Error 
In a normal healthy eye with no refractive error, beams of distant light enter the 
eye through the cornea where they are refracted through the lens in such a way so the 
focal point of those beams of light sits directly on the retina. This normal vision is also 
known as emmetropia.  
Myopia, also called nearsightedness, is a condition where the individual can see 
close objects clearly but experiences blurred vision when looking at objects farther away. 
This occurs because the refracting power of the cornea and lens is too strong, causing the 
beams of distant light entering the eye to be refracted too strongly so the focal point of 
those beams of light sits in front of the retina. In many cases, a contributing factor to this 
increased refracting power is a change in shape of the eyeball itself in such a way that the 
axial length is increased (Bastawrous, Silvester, & Batterbury, 2011). Myopia can be 
corrected by placing a spherical diverging (concave) lens in front of the ocular surface to 
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bend the entering beams of distant light in such a way as to move their focal point back to 
rest normally on the retina.  
Hyperopia, also called hypermetropia or farsightedness, is a condition where the 
individual can see objects that are far away clearly, but experiences blurred vision when 
looking at near objects. This occurs because the refracting power of the cornea and lens is 
too weak, causing the beams of distant light entering the eye to be refracted too weakly 
so the focal point of those beams of light sits theoretically behind the retina. In many 
cases, a contributing factor to this decreased refracting power is a change in shape of the 
eyeball itself in such a way that the axial length is decreased (Bastawrous, Silvester, & 
Batterbury, 2011). Hyperopia can be corrected by placing a spherical converging 
(convex) lens in front of the ocular surface to bend the entering beams of distant light in 
such a way as to move their focal point forward to rest normally on the retina. 
Presbyopia, also called age-related farsightedness, is a condition similar to 
hyperopia in that individuals can see objects that are far away clearly, but experiences 
blurred vision when looking at near objects. This occurs when the lens of the eye loses 
elasticity and becomes more rigid with age (Michael & Bron, 2011). This loss of 
elasticity correlates with an inability for the lens to change shape, also called 
accommodation, and thus loses refracting power (Cochrane, du Toit, & Le Mesurier, 
2010). This weak refracting power results in the same condition as hyperopia with the 
focal point of entering beams of distant light sitting behind the retina (Bastawrous, 
Silvester, & Batterbury, 2011). Presbyopia typically onsets in the mid-40s and worsens 
until age 65 (Boyd, 2013). It is corrected in the same manner as hyperopia by placing a 
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spherical converging (convex) lens in front of the ocular surface to bend the entering 
beams of distant light in such a way as to move their focal point forward to rest normally 
on the retina (Dowling & Dowling, 2016). 
Astigmatism is a condition that affects individuals suffering from by myopia or 
hyperopia where either the corneal surface of the eye or the curvature of the lens within 
the eye is irregularly shaped (Marcos et al., 2015). These two defects are called corneal 
astigmatism and lenticular astigmatism respectively. Shape irregularities in either the 
cornea or lens cause the beams of distant light entering the eye to refract in an irregular 
way, producing multiple focal points that do not all sit directly on the retina. This causes 
vision to become blurred at any distance. Astigmatism can further be divided into 
additional subgroups: regular and irregular astigmatism.  
Regular astigmatism includes: simple (one focal point always resting on the retina 
with one focal point resting behind the retina), compound (both focal points resting either 
in front or behind the retina), and mixed astigmatism (one focal point resting in front of 
the retina and one focal point resting behind the retina). Irregular astigmatism is 
astigmatism that is caused by some sort of irregularity of the cornea either by trauma, 
inflammation, scarring, or a developmental defect, which causes the cornea to deviate 
and change shape away from its normally expected curvature (Stein, Stein, & Freeman, 
2013).  
Regular astigmatism can be corrected by placing a special cylindrical lens in front 
of the ocular surface, which compensates for the irregular shape of the cornea or the lens 
and helps to focus the beams of distant light into a line instead of a point on the retina 
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(Stein, Stein, & Freeman, 2013). Irregular astigmatism, however, is much more difficult 
to treat and is often times not fully correctable using a cylindrical lens.  
Types of Vision Correction  
By far, the most common type of refractive error correction is corrective eyewear, 
or glasses. Over 150 million Americans currently wear some sort of corrective eyewear 
(“Eye Health Statistics,” n.d.). This is a very effective first step in vision correction, 
however, users can experience problems with wearing glasses. Depending on how high 
the prescription is, users can experience image distortion (Silberner, 1980) including 
image shrinking. Additionally, glasses can be cumbersome, expensive, and can break or 
be lost easily.  
 Another popular way to correct refractive errors is by utilizing prescription 
contact lenses. Contact lenses commonly come in two varieties: silicone or fluoropolymer 
soft lenses and rigid gas-permeable lenses (RGP). Contact lenses can be an excellent 
option to improve quality of life for individuals since they are easy to use and reduce 
dependence on glasses. However, contact lens users are also at risk for a number of 
complications. If contact lenses fit incorrectly, they can put an abrasive force on the 
ocular surface and increase the risk of corneal abrasion and neovascularization of the 
cornea (Boyd, 2016). Additionally, improper care can lead to increased risk for contact 
lens associated dry eyes and eye infections including conjunctivitis, keratitis and 
blepharitis (Stuart, 2012). These conditions can cause trauma or inflammation of the 
cornea, which can change the anterior corneal curvature, also called keratometry of the 
cornea, and lead to irregular astigmatism.  
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A semi-permanent way to correct refractive errors can be found in Implantable 
Contact Lenses (ICLs). While glasses and contact lenses are a good choice for the entire 
prescription spectrum from mild to strong lens prescriptions, ICLs are usually only 
recommended for moderately severely myopic (less than -4D) or hyperopic (less than 
+4D) individuals (Koivula & Zetterström, 2009). ICLs work by surgically opening the 
eye and implanting a phakic intraocular lens (IOL) either in front or behind the iris 
(Koivula & Zetterström, 2009). In either case, the ICL is placed in front of the natural 
lens. One positive aspect of ICLs is that if an individual’s visual acuity worsens, a new 
ICL of different refractive strength may be exchanged for the previously implanted one. 
However, ICLs present an increased risk of development of cataracts due to the ICL 
rubbing on the natural lens. Additionally, ICL users are at increased risk of infection and 
inflammation at the surgical site, pupillary block, endothelial cell death, as well as 
potential decrease in best corrected vision and onset of glares and halos (Stein, Stein, & 
Freeman, 2013). 
Since the 1960s, corneal refractive laser surgery (CRLS) has emerged as an 
extremely popular and effective way to permanently treat refractive errors (Silberner, 
1980). With the worldwide satisfaction rate after laser-assisted in situ keratomileusis 
(LASIK) surgery currently averaging 95.4% (Solomon et al., 2009), it is understandable 
that nearly 800,000 refractive surgical procedures were performed in the US in 2010 
(Helzner, 2010). The underlying idea behind refractive surgery is that since the cornea 
exerts the greatest influence on ocular refractive power, the corneal tissue can thus be re-
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shaped to increase or decrease the refractive power and allow for the focal point of 
distant light entering the eye to be moved to sit directly on the retina (Shah & Dua, 2000).  
During refractive surgery, the corneal tissue is re-shaped via a technique known 
as surface ablation using an excimer laser. Excimer lasers are a type of pulsed gas 
discharge laser that are set to produce an optical output in the ultraviolet spectrum of light 
(Basting, Dejeu, & Jain, 2005). These beams of light from the laser are fired toward a 
treatment zone on the cornea in a pulsatile fashion causing the molecular bonds of the 
surface tissue to be break and a certain amount of corneal tissue to be ablated (Alio, 
Rosman, & Mosquera, 2010). For correction of myopia, laser treatment with the intent to 
flatten or straighten the cornea is performed while in contrast, correction of hyperopia 
involves laser treatment with the intent to steepen the cornea (Adib-Moghaddam et al., 
2016).  
Anatomically, the cornea is avascular and made up of five distinct layers. From 
superficial to deep positioning those layers are: an external stratified squamous 
nonkeratinized epithelium, an anterior limiting membrane known as Bowman’s 
membrane, a thick bed of corneal stroma composed of type 1 collagen lamellae making 
up 90% of the corneal thickness, a posterior limiting membrane known as Descemet’s 
membrane, and an internal simple squamous endothelium sitting just superiorly to the 
anterior chamber of the eyeball (Mescher, 2016).  
In order for the excimer laser to reach the corneal stroma to ablate and change the 
shape of the stromal tissue bed, the superficial layer of external stratified squamous 
nonkeratinized epithelium and the associated Bowman’s membrane must be temporarily 
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displaced or removed. This epithelium is lifted in laser-associated in situ keratomileusis 
(LASIK) and laser epithelial keratomileusis (LASEK) and removed entirely in 
photorefractive keratectomy (PRK).  
LASIK 
 LASIK involves creating a flap in the cornea. This flap is usually created using a 
very small blade (microkeratome) or a femtosecond laser. A femtosecond laser is a type 
of infrared laser that works in conjunction with a suction ring and docking system to 
align the laser parallel with the ocular surface (Soong & Malta, 2009). Upon initiation, 
the laser generates microscopic gas bubbles within a horse-shoe shaped plane of cleavage 
under the ocular surface epithelium (Soong & Malta, 2009). Typical placement creates a 
superior flap hinge. After flap creation, the ophthalmologist performing the surgery is 
then able to loosen and lift the flap, exposing the underlying corneal stroma for ablation 
with an excimer laser. After ablation, the flap is re-positioned back in place and 
functional vision recovery can be expected within less than 24 hours with refractive 
stability achieved within 1 week to 3 months (Taneri, Weisberg, & Azar, 2011).  
LASEK 
 LASEK involves displacing the superficial epithelium overlying the laser 
treatment zone by means of producing an epithelial detachment by weakening the 
intercellular bonds within corneal epithelium with exposure to alcohol. Typically, 18-
20% medical grade ethanol is used and the epithelium is displaced with a superior or 
nasal hinge (Taneri, Zieske, & Azar, 2004). After laser ablation, the corneal epithelium is 
replaced over the treatment zone and a bandage contact lens is placed over the ocular 
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surface to help protect and facilitate healing (Taneri, Zieske, & Azar, 2004). Functional 
vision recovery can be expected within 3-7 days with full refractive stability achieved 
between 3 weeks to 3 months (Taneri, Weisberg, & Azar, 2011).  
PRK 
 PRK involves completely removing and discarding the superficial epithelium 
overlying the laser treatment zone by means of weakening the intercellular bonds within 
the corneal epithelium with exposure to alcohol. As with LASEK, typically 18-20% 
medical grade ethanol is used but in this case the epithelium is removed entirely with no 
intent to replace (Luger, Ewering, & Arba-Mosquera, 2012). After laser ablation the area 
is sometimes treated with Mitomycin C (MMC). MMC is a mitotic inhibitor that has been 
shown to help facilitate healing and prevent scarring by inhibiting keratinocyte and 
myofibroblast differentiation while the epithelium regenerates (Pinheiro et al., 2016). 
Though MMC is effective in preventing corneal subepithelial fibrosis and scarring, it has 
known carcinogenic properties and its use is decided on a case by case basis. Functional 
vision recovery can be expected within 3-7 days with full refractive stability achieved 
between 3 weeks to 3 months (Taneri, Weisberg, & Azar, 2011). 
Candidates for Refractive Surgery  
 According to Bastawrous, Silvester, & Batterbury (2011), the absolute criteria 
that must be met for candidacy for refractive surgery are: patients over 18 years of age 
with myopia up to 10 diopters or hyperopia up to 4 diopters and a stable lens prescription 
with less than 0.5 diopter change over one year. Absolute contraindications include 
unstable refraction, keratoconus, active infection or inflammation, and uncontrolled 
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glaucoma (Bastawrous, Silvester, & Batterbury, 2011). A stable refraction is essential for 
candidacy for refractive surgery as individuals with unstable refractions are more likely 
to need re-treatment or enhancement surgery in the future. Keratoconus is a condition in 
which the cornea experiences progressive central thinning leading to a central protrusion 
which may contribute to progressive myopia and irregular astigmatism (Ormonde, 2012). 
Patients with keratoconus are not candidates for refractive surgery as studies have 
demonstrated keratoconus patients who have undergone refractive surgery are at an 
increased risk of postoperative progressive ectasia (a non-inflammatory eye disorder 
characterized by central thinning of the cornea) and extension of the cornea (Ormonde, 
2012). Refractive surgery should only be performed on healthy eyes and as such, patients 
experiencing any sort of infection or inflammation should be treated prior to surgery. 
Lastly, studies have shown that refractive surgery can cause a transient rise in intraocular 
pressure and as such, patients with uncontrolled glaucoma are not good candidates for 
CRLS (Bastawrous, Silvester, & Batterbury, 2011).  
Additional consideration should be given to patients with dry eye syndrome, think 
corneas, blepharitis, cataracts, glaucoma, history of herpes simplex keratitis, ocular 
trauma, or previous ocular surgery as all of these can increase a patient’s probability of 
experiencing refractive surgery complications (Melki and Azar, 2001).  
The Cornea and Corneal Refractive Laser Surgery  
 As outlined above, there are several absolute criteria and contraindications for 
LASIK surgery relating to the cornea. Due to the nature of laser vision correction surgery 
re-shaping the cornea, it is imperative to perform multiple diagnostic and screening tests 
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to obtain as much information about the shape of the preoperative cornea so appropriate 
predictions can be made about the expected postoperative cornea. These screening 
criteria include: corneal topography, central corneal thickness, tear production, and 
corneal curvature.  
 Corneal topography, also known as photokeratoscopy, is commonly measured 
using either an OCULUS Pentacam or Ziemer Ophthalmology Galilei G4 machine. These 
non-invasive medical imaging devices utilize a an advanced placido disc system where a 
digital camera to focus on the anterior segment of the eye and quantify the corneal 
thickness pattern that is reflected back from the cornea (Luz et al., 2016). Each machine 
can collect up to 100,000 points of data across the surface of the cornea with a computer 
analyzing the results and presenting the information in a color-coded geographical 
formula, usually a sagittal map, according to the value of the corneal curvature (Stein, 
Stein, & Freeman, 2013). This information can then be used to determine any corneal 
shape irregularities, such as keratoconus or irregular astigmatism that could be 
contributing to refractive error. Additionally, the information can be used as a diagnostic 
tool to determine any irregularities that may arise or be exacerbated by CRLS and the 
corneal ablation that entails.  
 Corneal thickness is a measure of the amount of corneal stroma present in the eye 
in question and is usually measured by either a pachymeter or corneal topographer (such 
as the OCULUS Pentacam or Ziemer Ophthalmology Galilei G4). Values are given in 
diopters with a normal peripheral thickness of approximately 950µm and a normal central 
thickness of approximately 450µm (Stein, Stein, & Freeman, 2013). Central corneal 
	 
11 
thickness is essential in screening for corneal dysfunction including keratoconus. 
Depending on the patient’s manifest refraction and accompanying planned treatment of 
corneal stroma ablation to correct the refractive error, the actual thickness of residual 
stromal bed (RSB) is essential to know if the eye can withstand the planned ablation 
treatment. The amount of corneal stroma removed varies depending on the planned 
treatment and the surgeon must be cautious in screening the prospective patient, as too 
much thinning of the RSB increases the probability of the patient developing progressive 
ectasia or keratoconus postoperatively.  
 Due to the cornea being an avascular structure, it is entirely dependent on the 
diffusion of nutrients from the anterior chamber of the eye and tear film over the ocular 
surface. As such, tear production is important in maintaining the health of the cornea and 
contributes to its refractive power (Khurana, 2007). Laser vision correction surgery’s 
manipulation of the corneal surface and corneal stromal bed thus have an effect on the 
postoperative tear production and nourishment of the cornea. One of the possible side 
effects of refractive surgery is surgery-induced Dry Eye Syndrome (DES) with studies 
estimating that between 0.25% to 48% of patient’s undergoing CRLS experience DES 
either transiently or indefinitely after surgery (Bower et al., 2015). Tear production is 
always tested during initial surgery screening protocols and is usually done using a 
Schirmer Test or Oasis Medical ZoneQuick Test. Both of these tests evaluate normal tear 
production. Though patients with a lower than normal tear production can still undergo 
refractive surgery, they must be informed about the higher probably of them developing 
DES postoperatively.  
	 
12 
Lastly, corneal curvature as defined by flat and steep keratometry values are 
important because it is the corneal curvature that determines the refractive power of the 
cornea. Keratometry, also known as ophthalmometry, values can be given either in 
diopters when discussing the refractive power, or in millimeters when discussing the 
radius of curvature of the eye. Keratometry is an objective method to estimate the corneal 
astigmatism of the eye by measuring the central corneal curvature (Khuarana, 2007). It 
can be measured in multiple ways including manually using a keratometer, via an 
autorefractor, or via a corneal topographer (such as the OCULUS Pentacam or Ziemer 
Ophthalmology Galilei G4). Keratometers work by utilizing internal doubling prisms that 
reflect an image from two pairs of points on the cornea; the anterior corneal curvature 
and corneal power is then calculated using Snell’s Law of Refraction (assuming an Index 
of Refraction of 1.3375) from these four total reflected points (Stein, Stein, & Freeman, 
2013). On average, normal keratometry values range from 42-44 diopters indicating that 
is the normal refractive power of the central cornea (“Shape Curvature, and Power,” n.d.). 
Due to keratometry being an indicator of the refractive power of the cornea, keratometry 
values are thus related and important to understanding visual acuity. 
Visual Acuity and Keratometry 
Visual acuity (VA) is a test that has been developed over the years to accurately 
gauge how well a person can read at given distances based on a standardized chart. The 
standardized chart utilized most often for visual assessment is the Snellen Visual Acuity 
Chart consists of letters and/or numbers presented at a 5-minute angle to the eye at 20 
feet (6 meters). It is important to only use this chart at 20 feet as at that distance, the 
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distant rays of light entering the eye are parallel to each other and require very little 
accommodation by the lens (Stein, Stein, & Freeman, 2013). The actual VA testing result 
is expressed as a fraction, see Table 3. The numerator represents the distance between the 
patient and the chart letters while the denominator represents the distance between the 
patient and the chart letters at which a person with normal vision can see the chart letters. 
For example, if a person reads the 20/20 line at 20 feet, VA is 20/20 but if a person reads 
the 20/200 line at 20 feet, VA is 20/200. Normal distance vision is considered to be 
20/20.  
If a patient is not able to read the 20/20 line clearly, they will be refracted using a 
phoropter (Figure 1). This phoropter, also called a refractor, contains many trial spherical 
and cylindrical trial lenses mounted on circular wheels that can be interchanged quickly. 
An ophthalmic technician will determine the patient’s manifest refraction based on which 
lenses make the lines of the Snellen Visual Acuity Chart more clear.  
 
Figure 1: Phoropter (Refractor). Image showing both spherical and cylindrical trial lenses mounted 
internally on circular wheels for easy adjustment. Photo taken at Boston Eye Group/Boston Laser in 
Brookline, MA.  
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It has long been a longstanding belief in the ophthalmology community that if the 
cornea is re-shaped during vision correction surgery to such a degree that the 
postoperative keratometry falls below a certain value (historically given as <35D) 
rendering the cornea too “flat” that the best corrected (either surgically or surgically plus 
additional refraction) postoperative visual acuity will be diminished (Varssano et al., 
2013). Though literature and peer-reviewed journal articles are unclear in exactly how 
this idea came about since there is little evidence published to support the claim, there are 
several possible explanations for how this idea gained traction in the medical community. 
When specifically discussing LASIK procedures, multiple sources report that eyes with 
flat corneas can be at increased risk of developing flap complications including 
buttonholed flap or free cap.  
A buttonholed flap, also called a thin flap, is defined as when a flap is created 
within or above the Bowman’s membrane. In a normal flap, the bowman’s membrane 
will be lifted up with the overlying epithelium. However, in a buttonholed flap, the 
Bowman’s membrane (and thus full thickness of the ocular epithelium) is not lifted and is 
subsequently exposed to the excimer laser during ablation (Melki and Azar, 2001). This 
is problematic as the incomplete lifting of the epithelium can provide an easy route for 
epithelial cells to migrate along the corneal flap/stroma interface during the healing 
process and lead to epithelial ingrowth. Buttonhole flaps are a common complication 
leading to loss of BCVA postoperatively (Stulting et al., 1999).  
 A free cap is the unintended complete dissection (removal) of the corneal flap. As 
with buttonhole flaps, patient’s with flat corneas (K<42D preoperatively) are at an 
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increased risk of developing a free cap due to the flat angle of the cornea exposing less 
tissue during flap creation (Melki and Azar, 2001). In the best case scenario, if the cap 
can be retrieved it can be replaced in a manner similar to LASEK surgery. If the flap 
cannot be retrieved the epithelium will re-grow in a manner similar to PRK surgery. 
However, free caps can sometimes lead to a detrimental hyperopic shift (a weakening of 
the cornea’s refractive ability) that can greatly influence a patient’s postoperative BCVA 
(Amano et al., 2016).  
 Though corneal thickness and anterior corneal curvature are not the same thing, 
they are undoubtedly linked as you cannot change the thickness of the cornea without 
associatively changing the degree of curvature. Therefore, the amount of corneal stroma 
that can be removed by ablation can be limited by the predicted postoperative anterior 
corneal curvature and conversely. This has special importance for patients suffering from 
high degrees of myopia (spherical equivalent of -6D or greater) as the higher the 
prescription the greater the amount of corneal stroma that will need to be ablated. Several 
studies have reported greater incidence of under-correction (patients still remain myopic 
to some degree after surgery) in patients who ended up with flat corneas (K<38D) 
postoperatively (Mostafa, 2015 and Rao et al., 2001). This has been attributed to the 
possible loss of ablation efficiency for patients at corneal curvature extremes (flat or 
steep) as recommended by the current laser FDA guidelines (Mostafa, 2015).  
 Several papers have explored the relationship between measured preoperative 
keratometry values and VA outcomes after myopic CRLS. In 2001, Rao et al. examined 
preoperative keratometry’s relationship to postoperative VA in highly myopic (spherical 
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equivalent -6 to -13D) patients, followed by Christiansen et al. in 2012 who extended the 
investigation of preoperative keratometry and postoperative VA to moderately myopic 
(spherical equivalent -2 to -5.99D) patients. Additionally, whether preoperative 
keratometry has an influence on postoperative VA after hyperopic CRLS has also been 
explored (Cobro-Soriano et al., 2002; Williams, Dave, and Moshifar, 2008). However, 
current literature exploring the effect of either predicted postoperative keratometry values 
calculated using preoperative data, or measured postoperative keratometry values on 
postoperative visual acuity has not been extensively explored.  
 Three studies (Kim et al., 2011; Christiansen et al., 2012; Williams et al., 2008) 
looked at the overall change in keratometry values after myopic LASIK and PRK and any 
associated effect on visual acuity but did not explore if this change in keratometry left the 
patients with flat corneas after surgery. In 2013, Varssano et al. 2013 investigated the 
relationship between eyes that ended up with significantly flat corneas (K<35D) 
postoperatively and loss of BCVA in PRK patients, however they did not investigate if 
the degree of corneal flatness had any effect on BCVA or include any patients 
undergoing LASIK or LASEK surgery. In 2015, E. M. Mostafa explored the relationship 
between the degree of change in keratometry after CRLS and VA, however, he only 
investigated patients undergoing LASIK and limited his patient population to highly 
myopic (spherical equivalent -6 to -12D) patients. Also in 2015, Schallhorn et al. looked 
at postoperative keratometry but only investigated if there is a relationship with patient-
reported satisfaction and night-vision phenomena.  
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 Therefore, based on current literature searches, additional exploration of any 
relationship between postoperative keratometry including the degree of corneal flatness 
in any degree of myopic eyes undergoing any type of CRLS and loss of postoperative 
BCVA is warranted and will be explored in this thesis.  
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SPECIFIC AIMS 
 As reviewed in the introduction, there are many ways refractive errors can be 
corrected to improve vision. Furthermore, significant evidence shows that corneal 
refractive laser surgery (CRLS) is a safe and effective way to permanently correct these 
refractive errors. However, due to the pervasive idea in ophthalmology suggesting that 
patients with “flat corneas” or calculated predicted postoperative keratometry values of 
<35D, many of these patients are told they cannot be candidates for CRLS.  
The main objective of this paper was to retrospectively examine clinical data 
across all types of CRLS including LASIK, LASEK, and PRK to determine if there is 
evidence to substantiate this currently held idea that patients with a too flat anterior 
corneal curvature should not undergo CRLS. If there is in fact no demonstrated 
correlation between patients with flat corneas and loss of BCVA, this could have an 
impact on preoperative guidance for that patient population when considering candidacy 
for CRLS. 
The Specific Aims of the study are:   
1. To test if there is a correlation between candidate patients undergoing CRLS with 
predicted postoperative keratometry values of <38D and loss of best corrected 
visual acuity (BCVA).  
2. To test if there is a significant difference in visual acuity outcome between the 
degree of corneal flatness as measured by keratometry by placing patients into 
designated subgroups: Subgroup 1 (K<35D), Subgroup 2 (K=35-35.99D), 
Subgroup 3 (K=36-36.99D0 and Subgroup 4 (K=37-37.99D).  
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3. To examine the relationship between the type of surgery (LASIK, LASEK, or 
PRK) and patients who experienced a loss of BCVA after CRLS.  
We expect this study will show:  
1. There is no significant difference between patients with calculated predicted 
postoperative keratometry values <38D and patients with calculated predicted 
postoperative keratometry values of ≥38D with respect to loss of BCVA after 
CRLS.  
2. There is no significant difference between candidate patients placed further 
stratified groups based on the degree of corneal curvature: Subgroup 1 (K<35D), 
Subgroup 2 (K=35-35.99D), Subgroup 3 (K=36-36.99D) and Subgroup 4 (K=37-
37.99D).  
3. There is no significant difference between type of CRLS (LASIK, LASEK, or 
PRK) candidate patients underwent and subsequent postoperative BCVA.  
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METHODS 
Study Design Overview 
A retrospective chart review through the electronic health record, NextGen, was 
conducted for eyes that underwent LASIK, LASEK, or PRK corneal refractive laser 
surgery between December 2008 and November 2016. All reports were collected for 
patients undergoing surgery at the private ophthalmic practice Boston Eye Group/Boston 
Laser in Brookline, Massachusetts.  
The inclusion criteria for the study included patients with myopia who underwent 
LASIK, LASEK, or PRK between December 2008 and November 2016 and patients with 
mathematically calculated postoperative corneal curvature as measured by both flat and 
steep keratometry values estimated to be <38 diopters (see below for calculation). A 
manifest refraction matched control group of patients, meeting the same surgical and time 
frame period, with mathematically calculated postoperative corneal curvature values 
estimated to be equal to or greater than 38 diopters was included for control purposes.  
The exclusion criteria for the study was patients who underwent hyperopic laser 
vision correction surgery, patients who had undergone any other ocular surgeries prior to 
their LASIK, LASEK, or PRK with surface ablation screening evaluation, and patients 
who underwent enhancement surgery after the original LASIK, LASEK, or PRK laser 
vision correction surgery.  
Postoperative Keratometry Calculation 
Postoperative Keratometry values were calculated using a modified version of the 
mathematical formula suggested by Holladay et al. (2001) and Varssano et al. (2013). 
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The preoperative spherical equivalence was calculated using the preoperative manifest 
sphere and preoperative manifest cylinder and the formula: sphere + (cylinder/2). The 
spherical equivalence was then multiplied by 0.7. This calculation was performed to yield 
the approximate expected amount of corneal stroma to be ablated during surgery 
according to the 1:0.7 ratio as commonly accepted by the ophthalmological community. 
This estimated amount of corneal stroma expected to be removed via ablation was then 
subtracted from the measured preoperative keratometry values to yield the suggested 
calculated postoperative keratometry values.  
Clinical Laser Vision Correction Surgical Consultation Procedures 
As part of the preoperative laser vision correction surgery screening evaluation, 
all patients were required to undergo a thorough ocular examination to determine visual 
acuity including uncorrected visual acuity (UCVA) and best-corrected visual acuity 
(BCVA) along with both a manifest refraction using either an electronic or manual 
phoropter. Additional testing and imaging as part of the routine screening process 
included autorefraction with a Nidek Autorefractor (NIDEK ARK-530A, Fremont, 
California), ocular dominance, pupillometry using a handheld Oasis Medical Colvard 
Pupillometer (Oasis Medical Inc., San Dimas, California), tear production using Oasis 
Medical ZoneQuick (Oasis Medical Inc., San Dimas, California) Phenol Red Thread Tear 
Test, ocular tonometry using a Reichert Technologies Tono-Pen (AMETEK Inc., Depew, 
New York) or Nidek TONOREF II Non-Contact Tonometer (NIDEK Inc., Fremont, 
California), corneal pachymetry using a Corneo-Gage Plus pachymeter (Sonogage Inc., 
Cleveland, Ohio) and corneal topography using an OCULUS Pentacam (OCULUS Inc., 
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Arlington, Washington) prior to February 2014, or Ziemer Ophthalmology Galilei G4 
(Ziemer USA, Inc., Alton, Illinois) since February 2014. All tests were performed by 
ophthalmic technicians. Additionally, each patient underwent a cycloplegic refraction, 
dilated fundus examination, and slit-lamp examination by an ophthalmologist per Boston 
Eye Group/Boston Laser protocol. A total of 191 candidate eyes were identified to fit the 
inclusion criteria for this analysis within the study period which were subsequently 
matched with 191 control eyes for comparison.  
The following procedures are standard protocol for patients receiving laser vision 
correction surgery at Boston Eye Group/Boston Laser under the direction of 
ophthalmologist Dr. Samir Melki, MD, PhD.  
Pre-Operative Workup 
All patients were instructed to remain out of contact lenses for at least one week 
prior to surgery. Each patient was given the opportunity to meet with his or her surgeon 
either prior to surgery day or on the day of surgery to have all questions answered and 
addressed. On the day of surgery, upon check-in at Boston Eye Group/Boston Laser, each 
patient was instructed to fill out and sign all informed consent forms including 
medication consent(s) and all potential risks of each procedure via DocuSign and in-
person. Repeat testing of a manifest refraction or corneal topography were repeated if 
three months or more had elapsed since the initial surgery consultation, or if the patient 
had been wearing contact lenses on the day of initial surgery consultation. All repeat 
testing was performed by an ophthalmic technician and checked by the surgeon. Next, all 
patients were given both an oral and written outline of what each surgery entails and what 
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to expect before, during, and after that procedure. Patients were walked through all at-
home care instructions, follow-up eye drop regimens, and what to expect at each follow-
up appointment. Finally, 20-minutes prior to the expected surgery time, each patient was 
given 1-drop of the antibiotic Ciprofloxacin Hydrochloride Ophthalmic Solution 0.3% 
(Sandoz Inc., Princeton, New Jersey) and 1-drop of the anti-inflammatory Ilevro 
Nepafenac Ophthalmic Suspension 0.3% (Alcon Laboratories Inc, Fort Worth, Texas) to 
each pre-operative eye and one 5mg valium tablet by mouth to ease any day-of-surgery 
anxiety.   
Intra-Operative LASIK Procedure 
Each patient was brought into the Laser Suite at Boston Eye Group/Boston Laser 
(1101 Beacon Street Suite 6, Brookline, MA) and provided with a hair net prior to having 
them lay flat on the surgical bed with a surgical positioner placed under both knees. 
Sterile draping was performed with sterilization of the ocular surface of each surgical eye 
achieved using Betadine 5% Sterile Ophthalmic Prep Solution (Povidone-Iodine 
Ophthalmic Solution, Alcon Laboratories Inc., Fort Worth, Texas). Topical anesthesia of 
the ocular surface was achieved using 1% Proparacaine Hydrochloride Ophthalmic 
Solution (Alcon Laboratories Inc., Fort Worth, Texas). A Time-Out call was verbally 
called with patient name, date of birth, type of treatment and specific eye treatment was 
verified.  
Laser-assisted in situ keratomileusis (LASIK) flap formation involved using a 
femtosecond laser (IntraLase iFS60 Laser, Abbott Medical Optics Inc., Santa Ana, 
California) to create a corneal flap to allow for access to the corneal stromal tissue for 
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ocular surface laser ablation. Each corneal flap creation was set with an aim of a 9mm 
diameter flap and a superior hinge-position. Corneal flap depth, approximately between 
90 to 110 microns, is unique for each patient and determined using corneal topography 
and corneal thickness measurements (Kim et al., 2011) obtained at the patient’s initial 
surgical screening evaluation. Each of the patient’s measurements for flap position, 
diameter, and depth were double checked on the day of surgery.  
After corneal flap creation, the patient was rotated around and securely placed 
under an excimer laser (VISX STAR S4 IR Excimer Laser System, Abbot Medical 
Optics Inc., Santa Ana, California or WaveLight EX500 Excimer Laser, Alcon 
Laboratory Inc., Fort Worth, Texas). The patient’s upper eyelid was secured with a sterile 
Tegaderm Film (3M Health Care, St. Paul, Minnesota), a second drop of 1% 
Proparacaine Hydrochloride Ophthalmic Solution was applied, and an ocular speculum 
(Model OR 018, Titan Surgical, Kazan, Russia) placed to ensure the surgical eye 
remained open throughout the procedure. The surgical flap was then marked with a 
Regular Tip Latex-Free Sterile Marker (McKesson Medical Surgical, Richmond, 
Virginia) to ensure proper re-placement after laser application. The ocular surface was 
then irrigated with Balance Saline Solution (Alcon Laboratories Inc., Fort Worth, Texas) 
via a 25-gauge cannula (Model OC 022, Titan Surgical, Kazan, Russia) with a 3cc 
syringe (McKesson Medical Surgical, Richmond, Virginia) and dried with a Weck-Cel 
Cellulose Fluid Control Sponge (Xiomed, Jacksonville, Florida). If the planned surgical 
treatment cylinder was 1.5 or greater, the eye axis was marked on the ocular surface so 
laser crosshairs could be initiated to ensure accurate placement of the laser during 
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treatment. Pre-operative pachymetry was verbally called out. The corneal flap was then 
lifted using a LASIK spatula (Model OE 041, Titan Surgical, Kazan, Russia).  
 The exposed corneal stromal tissue was then ablated, i.e. treated for vision 
correction with the excimer laser (VISX STAR S4 IR Excimer Laser System or 
WaveLight EX500 Excimer Laser) to remove a certain amount of corneal stroma, 
measured in micrometers, from a set area of the ocular surface known as the ocular zone 
given in millimeters.  
Three-drops of a practice-specific steroid-antibiotic mixture of equally matched 
Prednisolone Acetate 0.1% Ophthalmic Solution (Sandoz Inc., Princeton, New Jersey) 
and Ciprofloxacin Hydrochloride Ophthalmic Solution 0.3% (Sandoz Inc., Princeton, 
New Jersey) was applied to the postoperative ocular surface. Gauze was taped over each 
surgical eye and the patient was taken out of the Laser Suite and to a dark examination 
room to rest for 30-minutes. After 30-minutes, each postoperative eye was thoroughly 
examined via slit-lamp examination to ensure proper flap placement and approximation 
of wound edges.  
Intra-Operative Advanced Surface Ablation (LASEK and PRK) Procedure 
 Each patient was brought into the Laser Suite at Boston Eye Group/Boston Laser 
and provided with a hair net prior to having them lay flat on the surgical bed with a 
surgical positioner placed under both knees. Sterile draping was performed with 
sterilization of the ocular surface of each surgical eye achieved using Betadine 5% Sterile 
Ophthalmic Prep Solution. Topical anesthesia of the ocular surface was achieved using 
1% Proparacaine Hydrochloride Ophthalmic Solution. A Time-Out call was verbally 
	 
26 
called with patient name, date of birth, type of treatment and specific eye treatment was 
verified.  
Using the microscope of an excimer laser (VISX STAR S4 IR Excimer Laser 
System or WaveLight EX500 Excimer Laser), the upper eyelid of the surgical eye was 
draped with a sterile Tegaderm Film, a second drop of 1% Proparacaine Hydrochloride 
Ophthalmic Solution was applied, and an ocular speculum (Model OR 018, Titan 
Surgical, Kazan, Russia) was placed to ensure eye opening throughout the procedure. 
One edge of a 9mm LASEK trephine (Model OK 048; Titan Surgical, Kazan, Russia) 
was marked with a Regular Tip Latex-Free Sterile Marker to visualize the ocular surgical 
treatment zone and for epithelium replacement after surface ablation. The LASEK 
trephine was then placed on the ocular surface and the central barrel filled with 20% 
ethanol solution (prepared with 2mL 100% medical grade ethanol mixed with 8mL sterile 
water) injected via 25-g cannula (Model OC 022, Titan Surgical, Kazan, Russia) for 40 
seconds. The 20% ethanol solution was applied with the intent to loosen and weaken the 
epithelium of the surface of the eye and removed using a Weck-Cel Cellulose Fluid 
Control to prevent spillage outside the trephine. After alcohol and trephine removal, the 
ocular surface was irrigated with Balanced Saline Solution (BSS) to wash away any 
remaining residual alcohol and re-hydrate the epithelium. During LASEK surgical 
procedures, the epithelium was lifted and displaced toward the limbal area and away from 
the optical ablation zone using a LASIK PVA Spear (Beaver-Visitec International Inc., 
Waltham, Massachusetts). During PRK surgical procedures, the epithelium was removed 
using another LASIK PVA Spear and Weck-Cel Cellulose Fluid Control Sponge.  
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The exposed corneal stromal tissue was then ablated with the excimer laser (VISX 
STAR S4 IR Excimer Laser System or WaveLight EX500 Excimer Laser) to remove a 
certain amount of corneal stroma, measured in micrometers, from a set area of the ocular 
surface known as the ocular zone given in millimeters. If the planned surgical treatment 
cylinder was 1.5 or greater, the eye axis was marked on the ocular surface so laser 
crosshairs could be initiated to ensure accurate placement of the laser during treatment.  
For LASEK surgeries, the epithelium was repositioned back into place using a 
LASIK PVA Spear with a bandage contact lens (Acuvue; Johnson & Johnson Vision 
Care Inc., Jacksonville, Florida) placed after surgery completion.  
For select patients undergoing PRK and laser vision correction, a bvi Merocel 
corneal light shield (Beaver-Visitec International Inc., Waltham, Massachusetts) 
saturated with the DNA crosslinking compound Mitomycin C (MMC) was applied to the 
corneal stroma after laser ablation for a variable time. Mitomycin C has been found to 
help facilitate healing and decrease corneal scarring (Hashemi et al., 2017). After ablation 
and/or MMC removal, the ocular surface was irrigated once again with BSS, the 
epithelium was not replaced, and a bandage contact lens was placed on the surface of the 
eye.  
After LASEK, three-drops of a practice-specific steroid-antibiotic mixture of 
equally matched Prednisolone Acetate 0.1% Ophthalmic Solution and Ciprofloxacin 
Hydrochloride Ophthalmic Solution 0.3% was applied to the postoperative ocular 
surface. 
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 After PRK, three drops of the same mixture of Prednisolone Acetate 1% 
Ophthalmic Solution and Ciprofloxacin Hydrochloride Ophthalmic Solution 0.3% in 
addition to one drop of the dilation solution Cyclopentolate Hydrochloride Ophthalmic 
Solution USP 1% (Bausch + Lomb Incorporated, Tampa, Florida) was applied to the 
postoperative ocular surface.  
Gauze was then taped over each surgical eye and the patient was taken out of the 
Laser Suite and to a dark examination room to rest for 30-minutes. After 30-minutes, 
each postoperative eye was thoroughly examined via slit-lamp. 
Post-Operative Procedure and Directions for LASIK 
 Immediately following slit-lamp examination, clear plastic eye shield(s) were 
placed over the patient’s surgical eye(s) prior to leaving the office. Patients were 
instructed to keep their eyes closed for 4 hours after surgery upon arrival at home, and 
keep the clear plastic eye shields in place every night for 1 week.  
 The daytime Boston Eye Group/Boston Laser eye drop regimen for 5 days after 
surgery is the following:  
• Pred Forte (Prednisolone Acetate 1% Ophthalmic Suspension USP), a topical 
anti-inflammatory agent.  
• Vigamox (Moxifloxacin Hydrochloride Ophthalmic Solution 0.5% as base), a 
fluoroquinolone antibiotic.  
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Table 1: Boston Eye Group/Boston Laser Postoperative LASIK Eye Drop Regimen 
 Day of 
Surgery 
Day 1 Day 2 Day 3 Day 4 Day 5 
Pred Forte 1 drop every 
hour 
1 drop 
every hour 
1 drop 
every hour 
4 drops per 
day 
4 drops per 
day 
STOP! 
Vigamox 4 drops per 
day 
4 drops per 
day 
4 drops per 
day 
4 drops per 
day 
4 drops per 
day 
STOP! 
 
Patients were instructed to wait 5 minutes between applying drops to prevent 
drops washing each other away. Due to the importance of keeping the ocular surface 
lubricated to prevent rough interaction with the eyelid, patients were encouraged to use 
preservative-free lubricating tears as needed. Additional instructions included:  
24 Hours: No squinting, squeezing, or rubbing the surgical eye(s) and no heavy 
lifting or strenuous physical activity.  
1 Week: no eye makeup, sunscreen, or lotion directly around the eyes.  
2 Weeks: no contact sports, swimming, hot tub, or Jacuzzi.  
Post-Operative Procedure and Directions for Advanced Surface Ablation  
 Immediately following slit-lamp examination, clear plastic eye shield(s) were 
placed over the patient’s surgical eye(s) prior to leaving the office. Patients were 
instructed to keep their eyes closed for 4 hours after surgery upon arrival at home, and 
keep the clear plastic eye shields in place every night for 1 week.  
 The daytime Boston Eye Group/Boston Laser eye drop regimen for 5 days after 
surgery is the following:  
• Pred-Gati (50:50 Mixture of Prednisolone Acetate 1% Ophthalmic Suspension 
USP and Gatifloxacin Ophthalmic Solution 0.5%), a topical anti-inflammatory 
agent and fluoroquinolone antibiotic. 
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• Nevanac (Nepafenac 0.1% Ophthalmic Suspension), a nonsteroidal anti-
inflammatory drug (NSAID). 
Table 2: Boston Eye Group/Boston Laser Postoperative LASEK and PRK Eye Drop Regimen 
 Week 1 (including 
surgery day) 
Week 2 Week 3 Week 4 
Pred-
Gati 
4 drops per day 2 drops per day 1 drop per day 1 drop per day 
until out 
Nevanac 2 drops per day if experiencing discomfort 
Vitamin 
C 
1 gram/100mg per day for 3 months to help prevent scarring 
 
Patients were instructed to space the drops evenly throughout the day and to wait 5 
minutes between applying drops to prevent drops washing each other away. Due to the 
importance of keeping the ocular surface lubricated to prevent rough interaction with the 
eyelid, patients were encouraged to use preservative-free lubricating tears as needed. 
Additional instructions included:  
• 24 Hours: No squinting, squeezing, or rubbing the surgical eye(s) and no heavy 
lifting or strenuous physical activity.  
• 1 Week: no eye makeup, sunscreen, or lotion directly around the eyes. Bandage 
contact lenses will be removed in office at Boston Eye Group/Boston Laser.  
• 2 Weeks: no contact sports, swimming, hot tub, or Jacuzzi.  
Additionally, each patient was given a prescription for Tylenol #3 with codeine to 
be taken as needed for postoperative discomfort.  
Follow-Up Procedures 
 All patients regardless of refractive surgery type were instructed to return to 
Boston Eye Group/Boston Laser for postoperative follow-up examinations at 1-day, 1-
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week, 6-weeks for LASIK or 9 weeks for Advanced Surface Ablation, 6-months, and 1-
year after surgery date.  
LASIK Follow-Up  
 At each LASIK postoperative examination, the patient was asked if they were 
experiencing any complaints including blurry vision, dryness, halos, trouble driving or 
trouble reading, and their right eye (OD), left eye (OS), and both eyes together (OU) 
distance visual acuity was checked. If the patient underwent LASIK Monovision, near 
visual acuity was also checked. At the 1-day postoperative examination, no intraocular 
pressure (IOP) or manifest refraction was performed. At the 1-week LASIK postoperative 
examination, a manifest refraction of both eyes was performed if the patient was not 
seeing 20/20 but no IOP was checked. Beginning at the 6-week LASIK postoperative 
examination, in addition to a manifest refraction of both eyes if not seeing 20/20, the 
patient’s IOP was checked using either Tono-Pen or Nidek TONOREF II Non-Contact 
Tonometer. Additionally, autorefraction, corneal topography, and/or Optical Corneal 
Tomography (OCT) of the macula were taken if patient not seeing 20/20. 
Advanced Surface Ablation Follow-Up 
 At each LASEK/PRK postoperative examination, the patient was asked if they 
were experiencing any complaints including blurry vision, dryness, halos, trouble driving 
or trouble reading, and their OD, OS, and OU visual acuity was checked. At the 1-day 
postoperative examination, no IOP or manifest refraction was performed. At the 1-week 
LASIK postoperative examination, no IOP was taken and bandage contact lenses were 
removed. All patients were given a manifest refraction if not seeing 20/20. Beginning at 
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the 9-week LASIK postoperative examination, in addition to a manifest refraction of both 
eyes if not seeing 20/20, the patient’s IOP was checked using either a Tono-Pen or Nidek 
TONOREF II Non-Contact Tonometer. Additionally, autorefraction, corneal topography, 
and/or Macular Optical Corneal Tomography (OCT) were taken if patient not seeing 
20/20.  
Data and Statistical Analysis  
All data was de-identified. Visual acuity, as measured as best corrected distance 
visual acuity (BCVA) given by the Snellen Visual Acuity Chart was converted to 
logMAR(BCVA) for more accurate statistical analysis (Holladay, 1997), see Table 3.  
Table 3: Snellen Visual Acuity Chart Conversion to LogMAR Equivalent. Adapted from Holladay, 
1997.  
Snellen Visual Acuity Chart Conversion to LogMAR 
Snellen Equivalent LogMAR Equivalent 
20/15 -0.125 
20/20 0 
20/25 0.1 
20/30 0.176 
20/40 0.3 
20/50 0.4 
20/60 0.477 
20/70 0.544 
20/80 0.6 
 
Candidate patients with calculated keratometry values <38D were separated from 
control patients with calculated keratometry values 38D and over. The candidate 
population data was further stratified with regard to calculated postoperative keratometry 
into four subgroups: Subgroup 1a (K<35D), Subgroup 2a (K=35-35.99D), Subgroup 3a 
(K=36-36.99D) and Subgroup 4a (K=37-37.99D). Accordingly, the control population 
data was also stratified with regard to calculated postoperative keratometry into four 
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subgroups: Subgroup 1b (K=38-38.99D), Subgroup 2b (K=39-39.99D), Subgroup 3b 
(K=40-40.99D) and Subgroup 4b (K≥41D). 
The Data Analysis tool in Microsoft Excel 15.26 was used for statistical analysis. 
The quantitative variables (means) were analyzed using the following tests: t-test, z-test, 
and ANOVA. A Two-Sample Assuming Unequal Variances two-tailed t-test was used to 
determine significance between candidate and control means of the preoperative manifest 
refraction, spherical equivalence, and total follow-up duration. To determine if there was 
a significant difference in preoperative vs. postoperative visual acuity outcomes between 
the overall candidate and control groups, a Two-Sample for Variances F-Test was used to 
determine equal or unequal variance and that variance was used to compute a Two 
Sample for Means z-test. To determine if there was a significant difference in 
preoperative vs. postoperative visual acuity outcomes between the candidate and control 
subgroups, a Single Factor Analysis of Variance (ANOVA) test was used to compare the 
multiple means. The qualitative variables (number of eyes that lost BCVA and number of 
eyes undergoing different surgery types) were analyzed using a Chi-Square Test for 
Independence.  
 The null hypothesis of all analysis tests assumed equal means or equal qualitative 
distribution. A p≤0.05 (probability less than 5%) was considered statistically significant 
and p≤0.01 (probability less than 1%) was considered very statistically significant leading 
to a rejection of the null hypothesis.  
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RESULTS 
Data information was collected from Boston Eye Group/Boston Laser chart 
records between December 2008 and January 2017. A total of 191 eyes (104 OD, 87 OS) 
belonging to 124 patients were identified as candidates. A control population of 191 
candidate eyes (104 OD, 87 OS) belonging to 123 individuals were selected by matching 
manifest refraction sphere and cylinder values with candidate patients.  
Preoperative Data 
 Data collected from the overall candidate group showed a mean preoperative 
manifest sphere refraction of -6.6D ± 1.95, mean manifest cylinder refraction of -1.23D ± 
1.03, mean spherical equivalence of -7.22D ± 1.86, mean flat keratometry of 41.46D ± 
1.24, and mean steep keratometry of 42.78D ± 1.41. Data collected from the 
corresponding overall control group showed a mean preoperative manifest sphere 
refraction of -6.49D ± 1.84, mean manifest cylinder refraction of -1.09D ± 0.90, mean 
spherical equivalence of -7.03D ± 1.68, mean flat keratometry of 44.31D ±1.32, and 
mean steep keratometry of 45.52D ± 1.29. A Two-Sample t-Test assuming Unequal 
Variance was used to compare candidate and control mean preoperative manifest sphere 
refraction (t(379) = -0.58, p = 0.55, two-tailed.), mean preoperative manifest cylinder 
refraction (t(373) = -1.46, p = 0.15, two-tailed.), and mean preoperative spherical 
equivalence (t(376) = -1.03, p = 0.30, two-tailed.). No significance was found between 
any of the previously mentioned comparisons.  
The mean candidate preoperative visual acuity, given in logMAR(BCVA), was 
0.0059 ±0.056 compared to the mean control preoperative logMAR(BCVA) of -2.9E-19 
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± 0.039. A z-test for means was conducted comparing these overall preoperative 
candidate and control means (z=1.20, p<0.23, two-tailed). Candidate vs. control 
preoperative visual acuity data is presented below (Figure 2).  
 
Figure 2: Candidate vs. Control Preoperative Visual Acuity. Graphical representation of the 
preoperative visual acuity of candidate patients with predicted postoperative keratometry values <38D vs. 
preoperative visual acuity of control patients with predicted postoperative keratometry values ≥38D. X-axis 
represents number of eyes; Y-axis represents visual acuity.  
 
 The candidate population data was further stratified with regard to calculated 
postoperative keratometry into four subgroups: Subgroup 1a (K<35D), Subgroup 2a 
(K=35-35.99D), Subgroup 3a (K=36-36.99D), and Subgroup 4a (K=37-37.99D). 
Accordingly, the control population data was also stratified with regard to calculated 
postoperative keratometry into four subgroups: Subgroup 1b (K=38-38.99D), Subgroup 
2b (K=39-39.99D), Subgroup 3b (K=40-40.99D), and Subgroup 4b (K=≥41D). See Table 
4 for a summary of these stratifications with regard to preoperative data. 
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Table 4: Candidate and Control Stratified Subgroups and Preoperative BCVA.  
Candidate: Preoperative BCVA 
 Subgroup 1a 
(K<35D) 
n=25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
P-value 
between 
Subgroups 
Mean BCVA: 
(logMAR(BCVA)) 
0.008 0.0111 0.0083 0.0004 0.77 
SD 0.028 0.032 0.088 0.035  
Range: 
(logMAR(BCVA)) 
0-0.1 0-0.1 -0.125-0.6 -0.125-0.1  
      
Manifest Sphere -8.2 -6.97 -6.63 -5.81 5.8E-7 
Manifest Cylinder -1.33 -1.58 -1.13 -1.10 0.10 
Spherical 
Equivalence 
-8.87 -7.76 -7.20 -6.36 5.0E-9 
      
Control: Preoperative BCVA 
 Subgroup 1b 
(K=38-
38.99D) 
n=76 
Subgroup 2b 
(K=39-
39.99D) 
n=70 
Subgroup 3b 
(K=40-
40.99D) 
n=24 
Subgroup 4b 
(K≥41D) 
n=21 
P-value 
between 
Subgroups 
Mean BCVA: 
(logMAR(BCVA)) 
-0.003 0.005 0 -0.007 0.53 
SD: 0.035 0.047 0 0.045  
Range: 
(logMAR(BCVA) 
-0.125-0.1 -0.125-0.3 0 -0.125-0.1  
      
Manifest Sphere -6.74 -6.7 -6.19 -5.20 0.004 
Manifest Cylinder -1.04 -1.18 -1.14 -0.90 0.616 
Spherical 
Equivalence 
-7.25 -7.29 -6.76 -5.65 0.0004 
 
A single factor analysis of variance (ANOVA) test was conducted to compare the 
following between candidate subgroups 1a, 2a, 3a and 4a: mean preoperative BCVA (no 
significance between the subgroup means, F(3, 187) = 0.374, p = 0.77), mean manifest 
sphere (statistically significant differences between the subgroup means, F(3, 187) = 
11.51, p = 5.8E-7), mean manifest cylinder (no significance between the subgroup means, 
F(3, 187) = 2.10, p = 0.10) and mean spherical equivalence (statistically significant 
differences between the subgroup means, F(3, 187) = 15.46, p = 5.0E-9).     
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Additional single factor ANOVA test was conducted to compare the following 
between control subgroup 1b, 2b, 3b and 4b: mean preoperative BCVA (no significance 
between the subgroup means, F(3, 187) = 0.741, p = 0.53), mean manifest sphere 
(statistically significant differences between the subgroup means, F(3, 187) = 4.65, p = 
0.004), mean manifest cylinder (no significance between the subgroup means, F(3, 187) = 
0.616, p = 0.61) and mean spherical equivalence (no significance between the subgroup 
means, F(3, 187) = 6.45, p = 0.0004). 
Postoperative Data 
Data collected from the candidate group showed a mean postoperative flat K of 
36.41D ± 1.07 and mean postoperative steep K of 37.73D ± 1.23. Data collected from the 
corresponding control group showed a mean postoperative flat keratometry of 39.39D 
±1.05, and mean postoperative steep keratometry of 40.60D ± 1.24. Candidate vs. control 
postoperative visual acuity data is presented below (Figure 3). 
 
Figure 3: Candidate vs. Control Postoperative Visual Acuity. Visual illustration of the postoperative 
BCVA of candidate patients with predicted postoperative keratometry values <38D vs. postoperative 
BCVA of control patients with predicted postoperative keratometry values ≥38D. X-axis represents number 
of eyes; Y-axis represents visual acuity.  
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The further stratified control subgroups with regard to postoperative visual acuity 
are presented below in Table 5.  
Table 5: Candidate and Control Stratified Subgroups and Postoperative BCVA. Top: Total number of 
persons in each stratified group and associated postoperative BCVA. Bottom: Total number of persons in 
each stratified control group and associated postoperative BCVA.  
Candidate: Postoperative BCVA 
 Subgroup 1a 
(K<35D) 
n=25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
Total: 
n=191 
Mean BCVA: 
(logMAR(BCVA)) 
0.026 0.001 -0.0004 -0.0032 0.006 
SD: 0.056 0.036 0.046 0.070 0.062 
Range: 
(logMAR(BCVA)) 
0-0.176 -0.125-0.176 -0.125-0.176 -0.125-0.4 -0.125-0.4 
      
Control: Postoperative BCVA 
 Subgroup 1b 
(K=38-
38.99D) 
Subgroup 2b 
(K=39-
39.99D) 
Subgroup 3b 
(K=40-
40.99D) 
Subgroup 4b 
(K≥41D) 
Total:  
Mean BCVA: 
(logMAR(BCVA) 
0.026 0.029 -0.004 -0.012 0.019 
SD: 0.092 0.119 0.067 0.038 0.097 
Range: 
(logMAR(BCVA) 
-0.125-0.544 -0.125-0.544 -0.125-0.1 -0.125-0 -0.125-0.544 
  
A single factor ANOVA test was conducted to compare the mean postoperative 
BCVA, reported in logMAR(BCVA), between candidate subgroups 1a, 2a, 3a and 4a, see 
Table 5. The analysis of variance showed no significance between the subgroup means, 
F(3, 187) = 1.8, p = 0.15. A second single factor ANOVA test was conducted to compare 
the mean postoperative BCVA between control subgroup 1b, 2b, 3b and 4b, see Table 5. 
The analysis of variance showed no significance between the subgroup means, F(3, 187) 
= 1.58, p = 0.20.  
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Loss of BCVA 
Of the overall candidate patient group, a total of 15 out of 191 eyes (7.85%) lost 
BCVA with 7 eyes losing 1 line of BCVA and 8 eyes lines losing 2+ lines of BCVA, see 
Figure 4. Of the overall control patient group, a total of 23 out of 191 eyes (12.04%) lost 
BCVA with 12 eyes losing 1 line of BCVA and 11 eyes losing 2+ lines of BCVA, Figure 
4. 
 
Figure 4: Candidate vs. Control vs. Total Loss of BCVA. Left: Candidate (7 eyes or 46.7% of candidate 
eyes losing BCVA) and Control (12 eyes or 52.2% of control eyes losing BCVA) Loss of 1 Line BCVA. 
Middle: Candidate (8 eyes or 53.3% of candidate eyes losing BCVA) and Control (11 eyes or 47.8% of 
control eyes losing BCVA) Loss of 2+ Lines BCVA. Right: Candidate (15 eyes) and Control (23 eyes) 
Loss of Total BCVA. X-axis represents number of eyes; Y-axis represents loss of BCVA categories.  
 
Further investigation into loss of postoperative BCVA by individual candidate 
and control subgroup is presented in Table 6 and Table 7 with both raw data numbers and 
relative frequencies within each subgroup.  
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Table 6: Candidate Eyes That Lost BCVA by Subgroup and Relative Frequency of Total Subgroup 
Population. The number of eyes within each subgroup that lost either 1 line or 2+ lines of BCVA as a 
percentage of each subgroup population where n is the number of subjects.   
 Subgroup 1a 
(K<35D) 
n= 25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
Total 
Candidates: 
n=191 
Loss of 1 Line 
BCVA  
3 (12.0%) 1 (2.8%) 2 (3.3%) 1 (1.4%) 7 (3.7%) 
Loss of 2+ 
Lines BCVA 
4 (16%) 1 (2.8%) 1 (1.7%) 2 (2.9%) 8 (4.2%) 
Total Loss of 
BCVA 
7 (28.0%) 2 (5.6%) 3 (5.0%) 3 (4.3%) 15 (7.9%) 
BCVA Not 
Lost 
 
18 (72.0%) 34 (94.4%) 57 (95.0%) 67 (95.7%) 176 (92.1%) 
 
Table 7: Control Eyes That Lost BCVA by Subgroup and Relative Frequency of Total Subgroup 
Population. The number of eyes within each subgroup who lost either 1 line or 2+ lines of BCVA as a 
percentage of each subgroup population.  
 Subgroup 1b  
(K=38-
38.99D) 
n=76 
Subgroup 2b  
(K=39-
39.99D) 
n=70 
Subgroup 3b  
(K=40-40.99D) 
n=24 
Subgroup 4b 
(K≥41D) 
n=21 
Total 
Controls:  
n=191 
Loss of 1 Line 
BCVA 
8 (10.5%) 0 (0%) 4 (16.7%) 0 (0%) 12 (6.3%) 
Loss of 2+ 
Lines BCVA 
8 (10.5%) 3 (4.3%) 0 (0%) 0 (0%) 11 (5.8%) 
Total Loss of 
BCVA 
16 (21.1%) 3 (4.3%) 4 (16.7%) 0 (0%) 23 (12.0%) 
BCVA Not 
Lost 
60 (82.2%) 67 (95.7%) 20 (83.3%) 0 (0%) 168 (88.0%) 
 
A chi-square test for independence was performed to examine if more eyes within 
the overall candidate group lost BCVA when compared to the overall control group. The 
relationship between these groups was not significant, X2 (1, N=382) = 1.87, p = 0.17. A 
second chi-square test for independence was performed to examine if more eyes within 
one particular candidate subgroup lost more BCVA when compared to the other 
respective candidate subgroups. The relationship between these subgroups was 
significant, X2 (3, N=191) = 16.19, p=0.001. A third chi-square test for independence was 
performed to examine if more eyes within one particular control subgroup lost more 
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BCVA when compared to the other respective control subgroups. The relationship 
between these subgroups was significant, X2 (3, N=191), = 13.16, p = 0.004.  
To better understand and statistically analyze the loss of BCVA within each 
subgroup, visual acuities were converted to logMAR(BCVA) and an overall mean visual 
acuity in logMAR(BCVA) was calculated before and after surgery for each particular 
subgroup. When comparing mean preoperative BCVA to mean postoperative BCVA 
within each subgroup, a single factor ANOVA test was conducted with the p-values 
presented below in Table 8 (candidate) and Table 9 (control).  
Table 8: Candidate Subgroup Mean Preoperative and Postoperative BCVA Comparison. Significant 
p-values are bolded.   
 Subgroup 1a 
(K<35D) 
n= 25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
Total 
Candidates: 
n=191 
P-value:  0.02 0.13 0.53 0.74 0.92 
 Table 9: Control Subgroup Mean Preoperative and Postoperative BCVA Comparison. Significant p-
values are bolded.  
 Subgroup 1b  
(K=38-
38.99D) 
n=76 
Subgroup 2b  
(K=39-
39.99D) 
n=70 
Subgroup 3b  
(K=40-
40.99D) 
n=24 
Subgroup 4b 
(K≥41D) 
n=21 
Total 
Controls: 
n=191 
P-value:  0.001 0.02 0.76 0.33 0.01 
 
Follow-Up Data 
The overall candidate group had a mean follow-up period of 283.59 days (9.34 
months) ranging from 1 day to 1613 days. In contrast, the overall control group’s mean 
follow-up period was 181.72 days (5.98 months) ranging from 1 day to 1455 days. A 
Two-Sample t-Test assuming Unequal Variance comparing the candidate and control 
mean follow-up durations was performed and a statistically significant difference was 
found, t(335) = 3.07, p = 0.002, two-tailed. The candidate and control subgroup data 
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including subgroup mean and standard deviation are presented below in Tables 10 and 
11, respectively.  
Table 10: Candidate Subgroup Follow-Up Duration 
 Subgroup 1a 
(K<35D) 
Subgroup 2a 
(K=35-35.99D) 
Subgroup 3a 
(K=36-36.99D) 
Subgroup 4a 
(K=37-37.99D) 
Overall: 
Follow-Up 
Mean (days): 
274.4 257.72 278.83 308.70 283.59 
SD: 396.86 361.87 367.70 417.12 378.89 
Range 
(days): 
1-1420 1-1420 1-1250 1-1613 1-1630 
 
Table 11: Control Subgroup Follow-Up Duration 
 Subgroup 1b 
(K=38-38.99D) 
Subgroup 2b 
(K=39-39.99D) 
Subgroup 3b 
(K=40-40.99D) 
Subgroup 4b 
(K≥41D) 
Total:  
Follow-Up 
Mean (days):  
207.04 156.37 238.04 110.19 181.72 
SD:  295.32 204.39 343.54 110.39 258.12 
Range 
(days): 
1-1287 1-1105 1-1455 1-444 1-1455 
 
A single factor ANOVA test was conducted to compare the mean follow-up 
duration, in days, between candidate subgroups 1a, 2a, 3a and 4a, see Table 12. The 
analysis of variance showed no significance between the subgroup means, F(3, 187) = 
0.156, p = 0.93. A second single factor ANOVA test was conducted to compare the mean 
follow-up duration, in days, between control subgroup 1b, 2b, 3b and 4b, see Table 13. 
The analysis of variance showed no significance between the subgroup means, F(3, 187) 
= 1.40, p = 0.25.  
Six of the candidate eyes were co-managed, meaning they did not return to 
Boston Eye Group/Boston Laser after their 1-day post-op and instead received their 
follow-up care from their regular ophthalmologist or optometrist who referred them for 
surgery. Seven of the control eyes were co-managed. 
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Surgery Type 
For the purposes of our results, due to the similarities in healing time and vision 
stabilization, LASEK and PRK were combined together as Advanced Surface Ablation 
(ASA). Of the 191 candidate patients, 123 (64.4%) underwent LASIK and 68 (35.6%) 
underwent ASA surgery. In contrast, of the 191 control patients, 108 (56.5%) underwent 
LASIK, 83 (43.5%) underwent ASA surgery. A chi-square test for independence was 
performed to examine the relationship between candidate and control groups versus 
surgery type (LASIK or ASA). The relationship between these groups was not 
significant, X2 (1, N=382) = 2.46, p = 0.12. 
 With regard to the candidate and control subgroups, surgery type is presented 
below in Table 12 and Table 13. 
Table 12: Candidate Surgery Type by Subgroup. Candidate eyes that underwent LASIK surgery (top 
row) and ASA (bottom row) stratified by subgroup (columns). Results given in raw data and relative 
frequency. 
 Subgroup 1a 
(K<35D) 
n=25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
Total 
Candidates:  
n=191 
LASIK 15 (60%) 29 (81%) 34 (57%) 44 (63%) 123 (64%) 
ASA 10 (40%) 7 (19%) 26 (43%) 26 (37%) 68 (36%) 
 
Table 13: Control Surgery Type by Subgroup. Control eyes that underwent LASIK surgery (top row) 
and ASA (bottom row) stratified by subgroup (columns). Results given in raw data and relative frequency.  
 Subgroup 1b 
(K=38-38.99D) 
n=76 
Subgroup 2b 
(K=39-39.99D) 
n=70 
Subgroup 3b 
(K=40-40.99D) 
n=24 
Subgroup 4b 
(K≥41D) 
n=21 
Total 
Controls:  
n=191 
LASIK 47 (62%) 42 (60%) 10 (42%) 9 (43%) 108 (57%) 
ASA 29 (38%) 28 (40%) 14 (58%) 12 (57%) 83 (43%) 
 
A chi-square test for independence was performed to examine if one particular 
candidate subgroup contained eyes that underwent a different surgery type distribution. 
The relationship between these groups was statistically significant, X2 (1, N=191) = 4.37, 
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p = 0.04. A second chi-square test for independence was performed to examine if one 
particular control subgroup contained eyes that underwent a different surgery type 
distribution. The relationship between these groups was not significant, X2 (1, N=191) = 
4.97, p = 0.27. 
Presented another way, the overall data of both candidate and control groups: 231 
eyes underwent LASIK with 17 total eyes losing BCVA (7.4%) and 214 (92.6%) not 
losing BCVA.  In contrast, 151 eyes underwent ASA with 21 total eyes losing BCVA 
(13.9%) and 130 (86.1%) not losing BCVA. A chi-square test for independence was 
performed to examine the relationship between overall postoperative BCVA (Loss of 
BCVA or No Loss of BCVA) and surgery type (LASIK or ASA). The relationship 
between these groups was significant, X2 (1, N=382) = 4.37, p = 0.04.  
Of the 15 candidate eyes that lost 1 or more lines of postoperative BCVA, 7 eyes 
(46.7%) underwent LASIK and 8 eyes (53.3%) underwent ASA. A chi-square test for 
independence was performed to examine if there was a difference in loss of BCVA 
between surgery type. The relationship between these groups was not significant, X2 (1, 
N=191) = 2.23, p = 0.14. These 15 candidate eyes had a mean follow-up period of 248.8 
days with a range from 1 day to 1420 days. Of the 8 candidate eyes that lost 1 or more 
lines of BCVA and underwent ASA, five eyes (62.5%) had the last documented follow-
up before expected vision stabilization (1 day(x3), 7 days, and 18 days). Normal vision 
stabilization for ASA is 3 weeks to 3 months (Taneri, Weisberg, & Azar, 2011). 
Of the 23 control eyes that lost 1 or more lines of postoperative BCVA, 10 eyes 
(45.5%) underwent LASIK and 13 eyes (56.5%) underwent ASA. A chi-square test for 
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independence was performed to examine if there was a difference in loss of BCVA 
between surgery type. The relationship between these groups was not significant, X2 (1, 
N=191) = 1.12, p = 0.29. These 23 control eyes had a mean follow-up period of 39.3 days 
with a range from 1 day to 473 days. Of the 13 control eyes that lost BCVA and 
underwent ASA surgery, eight eyes (61.5%) had the last documented follow-up before 
expected vision stabilization (1 day, 4 days(x2), 6 days(x3), and 7 days(x2)). Normal 
vision stabilization for ASA is 3 weeks to 3 months (Taneri, Weisberg, & Azar, 2011).  
Intraoperative Complications 
 Of the 191 candidate eyes, 17 eyes experienced intraoperative complications. 
Three LASEK eyes experienced an Epi Flap <180 (incomplete hemi-dissected flap), 5 
LASEK eyes experienced flap removal (this rendered each procedure equivalent to PRK), 
6 LASIK eyes experienced bubbles in the anterior chamber (AC) as a result of LASIK 
flap creation with a Femtosecond laser (requires the surgery be stopped for a length of 
time to allow the bubbles to dissipate naturally), 1 LASIK eye demonstrated a 2-4mm 
epithelial defect, 1 LASIK eye experienced a loss of suction during the first pass of 
docking with the Femtosecond laser with successful second pass, and 1 LASIK eye 
experienced a VBB (Vertical Gas Bubble Breakthrough) peripheral complication with the 
femtosecond laser flap creation. See Table 14 for complications within candidate 
subgroups breakdown. Of the 15 overall candidate eyes that lost BCVA, none 
experienced intraoperative complications.  
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Table 14: Eyes Within Candidate Subgroups Experiencing Intraoperative Complications. Raw 
numbers and relative frequencies  
 Subgroup 1a 
(K<35D) 
n= 25 
Subgroup 2a 
(K=35-
35.99D) 
n=36 
Subgroup 3a 
(K=36-
36.99D) 
n=60 
Subgroup 4a 
(K=37-
37.99D) 
n=70 
Total 
Candidates: 
n=191 
Epi Flap 
<180 
0 0 1 (1.7%) 1 (1.4%) 2 (1.0%) 
LASEK Flap 
Removal 
1 (4.0%) 0 3 (5.0%) 1 (1.4%) 5 (2.7%) 
Bubbles in 
AC 
0 2 (5.6%) 4 (6.7%) 0 6 (3.1%) 
Epi Defect 0 0 1 (1.7%) 0 1 (0.5%) 
Loss of 
Suction 1st 
Pass 
0 0 0 1 (1.4%) 1 (0.5%) 
VBB 0 0 1 (1.7%) 0 1 (0.5%) 
Total: 1 (4.0%) 2 (5.6%) 10 (16.7%) 3 (4.3%) 16 (8.4%) 
 
Of the 191control eyes, 26 eyes experienced intraoperative complications. Six 
LASEK eyes experienced an Epi Flap <180 (incomplete hemi-dissected flap), 16 LASEK 
eyes experienced flap removal, 2 LASIK eyes experienced bubbles in the anterior 
chamber as a result of LASIK flap creation with a Femtosecond laser, 1 LASIK eye 
demonstrated a 1mm epithelial defect, and 1 LASIK eye experienced a VBB peripheral 
complication with the Femtosecond laser flap creation. See Table 15 for complications 
within control subgroups breakdown. Of the 23 overall control eyes that lost BCVA after 
CRLS surgery, 18 eyes did not experience any intraoperative complications, 2 eyes 
experienced an Epi Flap <180, 2 eyes experienced flap removal, and 1 eye experienced a 
VBB peripheral complication. 
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Table 15: Eyes Within Control Subgroups Experiencing Intraoperative Complications. Raw numbers 
and relative frequencies.  
 Subgroup 1b  
(K=38-
38.99D) 
n=76 
Subgroup 2b  
(K=39-
39.99D) 
n=70 
Subgroup 3b  
(K=40-
40.99D) 
n=24 
Subgroup 4b 
(K≥41D) 
n=21 
Total 
Controls:  
n=191 
Epi Flap 
<180 
0 3 (4.3%) 1 (4.2%) 2 (9.5%) 6 (3.1%) 
LASEK Flap 
Removal 
1 (1.3%) 4 (5.7%) 4 (16.7%) 4 (19.0%) 13 (6.8%) 
Bubbles in 
AC 
0 1 (1.4%) 0 0 1 (0.5%) 
Epi Defect 0 0 0 1 (4.8%) 1 (0.5%) 
Loss of 
Suction 1st 
Pass 
0 0 0 0 0 
VBB 1 (1.3%) 0 0 0 1 (0.5%) 
Total: 2 (2.6%) 8 (11.4%) 5 (20.8%) 7 (33.3%) 22 (11.5%) 
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DISCUSSION 
This study was performed with the objective of exploring if patients undergoing 
CRLS with mathematically calculated postoperative keratometry values of <38D are at 
greater risk of losing one or more lines of BCVA after surgery. Furthermore, we wished 
to examine if the degree of corneal curvature flatness as designated by mathematically 
calculated postoperative keratometry values (K<35D, 35-35.99D, 36-36.99D, and 37-
37.99D) was related to postoperative loss of BCVA, and if type of CRLS (LASIK vs. 
ASA) had any type of contributing role in predicting postoperative visual acuity.  
Candidate-Control Matching 
 In terms of preoperative data, the lack of significant differences between overall 
visual acuity, manifest refraction (sphere and cylinder) and spherical equivalence 
demonstrates the candidates and controls were not significantly different with regard to 
planned treatment. Additionally, the lack of significant difference between percentage of 
eyes undergoing surgery type (LASIK or ASA) provides additional evidence that 
candidate and control patient populations were well matched. This demonstrates that any 
differences in postoperative visual acuity outcome between the overall candidate and 
control groups was not due to candidate-control mismatching and do not need to be 
considered further as confounding factors.   
Overall Loss of BCVA 
 Numerically, 15 (7.85%) candidate eyes lost 1+ lines of BCVA compared to 23 
(12.04%) control eyes that lost 1+ lines of BCVA. This result was not significant 
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(p<0.17) indicating there was no evidence of an overall difference between instances of 
loss of BCVA between candidate eyes (K<38D) and control eyes (K≥38D).  
 Though not significant, these results indicating the control population actually had 
more eyes that lost postoperative BCVA compared to the candidate population, is not 
what we hypothesized and is different that the results found by Varssano et al. (2013). 
Varssano et al. (2013) found that when comparing the proportion of eyes with flat 
corneas (K<35D) and control eyes (K≥35D) who lost 1 or more lines of BCVA, there 
was no significant difference between the groups. There are several possible explanations 
for this discrepancy between our study and that 2013 study’s results. First, our candidate 
groups were different. Varssano et al. (2013) studied eyes with flat corneas as defined by 
keratometry values under 35D whereas we studied candidate eyes with flat corneas as 
defined by keratometry values under 38D. However, we did subdivide our candidate 
group to include a K<35D subgroup with the results of this division discussed later. 
Second, Varssano’s mean preoperative and mean postoperative data was different than 
ours. Varssano et al. (2013) found that their control group (K<35D) exhibited 
significantly worse mean preoperative BCVA and mean postoperative BCVA when 
compared to the control group (K≥35D) whereas we found no significant difference in 
overall mean preoperative BCVA and overall mean postoperative BCVA between our 
candidate and control groups.  
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Subgroup Loss of BCVA 
 A significant difference (p<0.001) was found between candidate subgroups when 
comparing loss of BCVA indicating that one or more subgroups contained more eyes that 
lost BCVA when compared to the other candidate subgroups. 
 Candidate Subgroup 1a (K<35D) had significantly worse postoperative visual 
acuity (p<0.02) when compared to preoperative visual acuity. This significant difference 
was not seen within the other candidate subgroups indicating Candidate Subgroup 1a 
contained significantly more eyes that lost 1 or more lines of BCVA compared to the 
other candidate subgroups.  This is evident in the raw data with 28% of eyes experiencing 
BCVA loss after CRLS. This data is again different from Varssano et al. (2013). They 
found that their K<35D group had significantly worse preoperative and postoperative 
BCVA but no overall greater proportion of eyes that lost BCVA compared to the K≥38D 
group. Our data was the exact opposite with no significantly worse preoperative or 
postoperative BCVA compared to other subgroups, but a significantly greater proportion 
of eyes that lost BCVA. One possible explanation for this is that the data presented in this 
study is a random sampling of a larger data set. It is possible that the smaller sample size 
and sampling process could have contributed to our differing data due to sampling error.  
A second study carried out by E. M. Mostafa in 2015 discussed visual acuity with 
regard to flat corneas. He focused on stratification of patients by degree of myopia (-6 to 
-7.9D, -8 to -9.9D, and -10 to -12D) and measured postoperative corrected distance visual 
acuity (CDVA) in patients with postoperative keratometry values <35D. His results were: 
0.0±0.6 in the -6 to -7.9D group, 0.1±1.2 in the -8 to -9.9D group, and 0.13±1.3 in the -10 
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too -12D group. This data shows eyes with flat corneas and higher myopia degrees of 
myopia experienced worse postoperative CDVA outcomes but is difficult to relate to our 
data due to our project not stratifying patients by degree of myopia and Mostafa not 
stratifying patients by degree of corneal flatness groups as we did.   
 One possible explanation for our Candidate Subgroup 1a showing significant 
differences is that this subgroup had significantly higher myopia with a higher mean 
preoperative manifest spherical refraction (-8.2D) and mean preoperative spherical 
equivalence (-8.87D) when compared to the other candidate subgroups (see Table 4 in 
results section). Several studies over the years have indicated that patients with higher 
myopia, -8 to -14D, are at increased risk of losing BCVA if they undergo CRLS which 
were summarized in a recent Cochrane Review paper (Barsam, 2014). Additionally, 
higher myopia requires a percentage of corneal tissue to be altered (PTA) by laser surgery 
(Santhiago et al., 2016) and if patients already have flat corneas, a high PTA could put 
the patient at risk of removing too much corneal tissue, increasing their risk for ectasia 
postoperatively, and making the cornea too weak to refract effectively.  
Another explanation for our Candidate Subgroup 1a showing significant 
differences could be if those eyes experienced a shorter follow-up duration that did not 
allow for full vision stabilization. However, analysis of follow-up data did not identify a 
significant difference in follow-up duration between candidate subgroups with Candidate 
Subgroup 1a experiencing an average follow-up duration of 274.4 days (see Table 12 in 
results section). This duration is short when considering patients are normally followed 
for 1 year after CRLS, but is not significantly different than the follow-up durations of 
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other candidate subgroups, or the overall candidate group, that did not lose postoperative 
BCVA.  
A third explanation for our Candidate Subgroup 1a showing significant 
differences could be if those eyes experienced more intraoperative complications. 
However, again this was not the case as of the 17 candidate eyes that experienced 
intraoperative complications during CRLS, only 1 eye (LASEK flap removal) was part of 
the Candidate Subgroup 1a. Furthermore, a LASEK flap removal complication 
essentially renders the operation equivalent to PRK which does not have an increased risk 
of visual acuity reduction or BCVA loss.  
Varssano et al. (2013) reported a mean follow-up period of 326± 327 days which 
is significantly longer than our paper which could contribute to our differing results. 
Mostafa (2015) did not report a follow-up period. Neither of the papers mentioned 
previously, Varssano et al. (2013) and Mostafa (2015), discussed intraoperative 
complications. A thorough literature review did not identify any additional studies that 
explored visual acuity outcomes in patients with flat corneas (either K<35D or K≥38D), 
therefore we have no other data to compare.  
Additionally, a significant difference (p<0.004) was found between control 
subgroups when comparing loss of BCVA indicating that one or more subgroups 
contained more eyes that lost BCVA when compared to the other control subgroups.  
Control Subgroup 1b (K=38-38.99D) and Control Subgroup 2b (K=39-39.99D) 
exhibited significantly worse postoperative visual acuity (p<0.001 and p<0.02 
respectively) when compared to preoperative visual acuity. In terms of raw data, 21% of 
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eyes in Control Subgroup 1b experienced BCVA loss after CRLS while 4.3% of eyes in 
Control Subgroup 2b experienced BCVA loss after CRLS. Additionally, both Candidate 
Subgroup 3a and Candidate Subgroup 4a experienced higher or similar percentages of 
intraoperative complications (16.7% and 4.3% respectively), making intraoperative 
complications leading to loss of preoperative BCVA unlikely.  
Again, possible explanations for these groups significant differences could 
potentially be preoperative myopia, follow-up duration, and intraoperative complications. 
Both Control Subgroup 1b and Control Subgroup 2b exhibited significantly higher 
degrees of myopia compared to the other two control subgroups with mean preoperative 
spherical manifest of -6.74D and -6.7D respectively and mean preoperative spherical 
equivalence of -7.25D and -7.29D respectively. It is interesting to note these values are 
nearly identical and they offer evidence that preoperative spherical manifest and spherical 
equivalence as relating to planned corneal tissue to be altered could account for an 
important impact on postoperative visual acuity. With regard to follow-up duration, all 
control subgroup follow-up durations were shorter than candidate durations, however, 
Control Subgroup 1b and Control Subgroup 2b did not have significantly shorter follow-
up durations when compared to their control subgroup counterparts.  
Lastly, Control Subgroup 1b contained two eyes that experienced intraoperative 
complications (flap removal and VBB) and Control Subgroup 2b contained eight eyes 
that experienced intraoperative complications (3 Epi Flap <180, 4 flap removal and 1 
bubbles in AC). Though these raw numbers may seem high, when relative frequency is 
taken into account, these complications only represent 2.6% of Control Subgroup 1b and 
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11.4% of Control Subgroup 2b. Additionally, both Control Subgroup 3b and Control 
Subgroup 4b experienced much higher rates of intraoperative complications (20.8% and 
33.3% respectively), making intraoperative complications influencing loss of 
postoperative BCVA less likely.  
A thorough literature review did not identify any additional studies that 
investigated visual acuity outcomes in patients grouped and stratified by keratometry 
values over 38D so we have no data with which to compare and contrast. 
It is important to note that our finding that the control eyes experienced a higher 
loss of BCVA postoperatively is different than the majority of articles studying visual 
acuity and patient satisfaction in post-CRLS patients. As stated previously patient 
satisfaction after LASIK is approximately 95.4% (Solomon et al., 2009), with patient 
satisfaction after ASA very similar (Diakonis et al., 2014). A possible explanation for our 
data’s deviation from the accepted norm of LASIK/ASA success rates is that we did not 
have a true randomized control sample. Our control sample was matched to manifest 
refraction and spherical equivalence to the control sample who exhibited higher than 
average treatment plans. Additionally, our control group’s significantly shorter follow-up 
duration when compared to the candidate patients most likely contributed to this apparent 
loss of BCVA as vision stabilization was not achieved in many patients.  
Surgery Type 
Given that there was no significance between the overall percentages of 
candidates undergoing LASIK or ASA and overall percentages of controls undergoing 
LASIK or ASA, this offers relevant evidence the candidate and control groups were well 
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matched by surgery type. Additionally, the lack of significance between candidate and 
control subgroups with regard to choice of surgery shows that not only were the 
candidate eyes well matched to the control eyes but there was similar breakdown of 
surgery type across subgroups.  
However, when looking at total candidate and control eyes that lost BCVA versus 
eyes that did not lose BCVA, significantly more eyes that lost BCVA underwent ASA 
(7.4% LASIK vs. 13.9% ASA). A possible explanation for this lies in the follow-up 
duration of eyes undergoing ASA. Approximately 62.5% of the candidate eyes and 
61.5% of the control eyes that lost BCVA and underwent ASA had follow-up durations 
shorter than the recommended time for vision stabilization.  
The data makes it impossible to rule out choice of surgery (LASIK or ASA) as a 
confounding factor for loss of postoperative BCVA. However, the inconsistency in 
follow-up duration indicates no clear conclusion can be made with regard to the influence 
of type of CLRS on postoperative vision outcomes.  
 We were not able to find any literature investigating the effect of LASIK or ASA 
choice on postoperative visual acuity outcomes in flat corneas. Varssano et al. (2013) 
only investigated patients undergoing PRK whereas Mostafa (2015) only investigated 
patients undergoing LASIK.  
Current Study Limitations and Future Studies 
 The first major limitation of this study is the use of mathematically calculated 
predicted postoperative keratometry values. Though the practice of using a mathematical 
formula and preoperative data to predict if a patient is a good candidate for CRLS from a 
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corneal curvature point of view is quite commonplace (Varssano et al., 2013), there is 
still a question of the validity of this mathematical formula as a prediction tool due to 
lack of studies performed to test the correlation between predicted and measured 
postoperative keratometry values. Further large-scale controlled studies to test this 
correlation are warranted. 
 For the purposes of this thesis, only mathematically calculated postoperative 
keratometry values were used. To further test the validly of this study, measured 
postoperative calculations and their correlation with postoperative visual acuity would 
offer greater evidentiary support to our findings and provide a more accurate exploration 
of the relationship between postoperative keratometry and visual acuity. Again, further 
large-scale controlled studies to test this relationship are warranted. 
 Next, though 191 candidate and 191 control eyes are significant enough to make 
this thesis study valid, sampling error due to a small sampling size could have possibly 
skewed our results. Future studies should take steps to avoid this by increasing sample 
size to include larger and more significant patient population.  
Another potential limitation of this thesis is the lack of uniformity in follow-up 
durations both within and between the candidate and control groups. In future studies, a 
minimum follow-up duration of 3 weeks should be set as part of the inclusion criteria to 
ensure all patients have experienced vision stabilization.  
Though patients were screened with a questionnaire for past ocular disorders or 
surgeries, it is possible that some patients suffered from undiagnosed diseases or 
disorders of the macula. In a future study, candidate screening protocols could include a 
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Macular Optical Coherence Tomography (OCT) to rule out any retinal changes which 
could account for a change in vision outcome. Additionally, patients were not evaluated 
for postoperative complications such as Dry Eye Syndrome (DES) or ectasia. Beyond 
glare and halos which can reduced patient’s satisfaction with CLRS postoperatively but 
do not necessarily have an impact on visual acuity, both DES and ectasia can reduce 
visual acuity postoperatively. These could potentially be addressed in future studies to 
reduce the number of possible confounding factors.  
In conclusion, though our study provided evidence that there is no relationship 
between our overall group of patients who end up with a corneal curvature of K<38D 
after surgery and loss of BCVA. However, our data did indicate that when the candidate 
group was stratified by degree of corneal curvature, eyes with very flat corneas (K<35D) 
may be at in increased risk of losing BCVA after CRLS. Further studies including an 
expanded patient population and follow-up duration should be carried out in the future. 
With regard to the relationship between visual acuity outcomes and type of surgery 
undergone, our data provided evidence that eyes undergoing ASA may be at increased 
risk of losing BCVA though further studies are needed.  
Additionally, the main goal of this thesis was to determine if there is a 
relationship between flat corneas and loss of postoperative BCVA. Further studies should 
be conducted to explore in more detail why a loss of BCVA may occur in flat corneas.  
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